New Progress in the Mechanism of Metformin Therapy for Polycystic Ovary Syndrome
LI Dan-ping
LIAN Fang
XIANG Shan
Abstract：Polycystic ovary syndrome(PCOS)is a common reproductive endocrine disease,mainly manifested by ovulation disorders,menstrual cycle disorders,hyperandrogenemia,etc.,and often accompanied by insulin resistance,obesity and metabolic abnormalities.The pathogenesis of PCOS involves genetic factors,environmental factors,chronic inflammation,autoimmune and so on.Metformin as an AMP-activated protein kinase(AMPK)activator can enhance insulin sensitivity and decrease AMPK-cyclic adenosine monophosphate(cAMP),and thereby reduce the expression of gluconogenic enzymes.Metformin can promote follicle development and maturation,improve insulin resistance and restore the menstrual cycle,by relieving chronic inflammation,resisting oxidative stress,restoring mitochondrial function,inhibiting ferroptosis,and many other aspects.In addition,the activation of AMPK by metformin is closely related to the reduced risk of cardiovascular disease and the alleviation of liver damage in PCOS patients.The mechanism of AMPK activated by metformin in the treatment of PCOS was reviewed in this paper.
Keywords：Polycystic ovary syndromeMetforminAMP-activated protein kinasesTherapy
Publication Date：2024-07-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 343-347 )